Table 1

Epidemiological data and comorbidities of patients included in the study distributed by diagnostic category; [n (%)] except where indicated
Total Colonised Aspergillosis
Probable Proven Probable + Proven
No. Patients 245 106 125 14 139
Age (mean ± SD) 68.7 ± 15.2 69.1 ± 16.1 68.9 ± 14.6 64.1 ± 14.5 68.4 ± 14.6
Males 171 (69.8) 67 (63.2) 94 (75.2) 10 (71.4) 104 (74.8)a
Comorbiditiesb
COPD 173 (70.6) 73 (68.9) 91 (72.8) 9 (64.3) 100 (71.9)
   Gold III + IVc 111 (67.3) 40 (57.2) 66 (76.7)a 5 (55.6) 71 (74.7)a
Diabetes Mellitus II 43 (17.6) 19 (17.9) 23 (18.4) 1 (7.1) 24 (17.3)
Congestive heart failure 45 (18.4) 13 (12.3) 27 (21.6) 5 (35.7)a 32 (23.0)a
Malignancies 38 (15.5) 10 (9.4) 27 (21.6)a 1 (7.1) 28 (20.1)a
Renal impairment 24 (9.8) 10 (9.4) 12 (9.6) 2 (14.3) 14 (10.1)
Charlson (mean ± SD) 2.61 ± 2.16 2.42 ± 2.03 2.81 ± 2.29 2.21 ± 1.76 2.75 ± 2.75
APACHE (mean ± SD) 13.16 ± 6.86 11.63 ± 6.12 14.13 ± 6.67a 16.14 ± 10.90 14.33 ± 7.18a
ICU admission at any time during hospital stay 58 (23.7) 15 (14.2) 36 (28.8)a 7 (50.0)a 43 (30.9)a

ap ≤ 0.050 vs. colonised; bpresent in ≈ > 10% total patients; camong patients with available data (165 patients in total: 70 colonized, 86 probable and 9 proven).

Barberan et al.

Barberan et al. BMC Infectious Diseases 2012 12:295   doi:10.1186/1471-2334-12-295

Open Data